218 related articles for article (PubMed ID: 33073529)
1. Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology.
Weddell J; Chiney MS; Bhatnagar S; Gibbs JP; Shebley M
Clin Transl Sci; 2021 Jan; 14(1):395-404. PubMed ID: 33073529
[TBL] [Abstract][Full Text] [Related]
2. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
[TBL] [Abstract][Full Text] [Related]
3. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
[TBL] [Abstract][Full Text] [Related]
4. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
[TBL] [Abstract][Full Text] [Related]
5. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
6. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class.
Calopiz MC; Linderman JJ; Thurber GM
Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
9. Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates.
Matsuda Y; Seki T; Yamada K; Ooba Y; Takahashi K; Fujii T; Kawaguchi S; Narita T; Nakayama A; Kitahara Y; Mendelsohn BA; Okuzumi T
Mol Pharm; 2021 Nov; 18(11):4058-4066. PubMed ID: 34579528
[TBL] [Abstract][Full Text] [Related]
10. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
11. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
12. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
13. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
14. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
[TBL] [Abstract][Full Text] [Related]
15. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
16. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.
Haddish-Berhane N; Shah DK; Ma D; Leal M; Gerber HP; Sapra P; Barton HA; Betts AM
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):557-71. PubMed ID: 23933716
[TBL] [Abstract][Full Text] [Related]
17. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
Burton JK; Bottino D; Secomb TW
AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
[TBL] [Abstract][Full Text] [Related]
18. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer.
Cherifi F; Da Silva A; Martins-Branco D; Awada A; Nader-Marta G
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):45-59. PubMed ID: 38214896
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]